Pharmacotherapy in erectile dysfunction agents for self-injection programs and alternative application models

H. Hedlund, P. Hedlund

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Previously, men with erectile dysfuncion (ED) were frequently treated with penile prosthesis implants or considered to have psychogenic impotence. Since the reports by Virag and Brindley in 1982 and 1983, pharmacotherapy, by self-injection programs has become a new therapeutic concept for impotent men. In clinical practice, this application model has been generally accepted as the 'golden standard' in the treatment of ED. Papaverine was first used as monotherapy, but because of side-effects such as prolonged erection, priapism, and fibrosis of the corpus cavernosum, single use of the drug was abandoned. Instead, papaverine was introduced in mixtures, e.g. together with α-adrenoceptor-blockers as phentolamine, and/or prostaglandin E1 (PGE 1). In these 'cocktails', the dose of papaverine is reduced to 10-15 mg, compared to the high doses (80-120 mg) that were used initially. By having two or more drugs in the mixture, a facilitating cascade effect is probably obtained. PGE 1 is the only drug that has been approved by the FDA and is today registered in more than 50 countries. Other combination therapies such as vasoactive intestinal polypeptide + phentolamine, or calcitonin gene-related peptide + PGE 1, have been suggested as suitable alternatives for intracavernosal injection. Transdermal and intraurethral application models may be considered in selected patients. Recently, oral administration of a phosphodiesterase inhibitor (UK-92.480) was reported to improve penile erection in patients with psychogenic impotence. Further clinical results from controlled trials will probably explain if this new oral drug will compete with PGE 1 or other agents in self-injection programs.

Original languageEnglish
Pages (from-to)129-138
Number of pages10
JournalScandinavian Journal of Urology and Nephrology, Supplement
Volume30
Issue number179
Publication statusPublished - 1996

Fingerprint

Alprostadil
Erectile Dysfunction
Papaverine
Penile Prosthesis
Drug Therapy
Injections
Phentolamine
Pharmaceutical Preparations
Priapism
Penile Erection
Phosphodiesterase Inhibitors
Calcitonin Gene-Related Peptide
Vasoactive Intestinal Peptide
Controlled Clinical Trials
Adrenergic Receptors
Prostheses and Implants
Oral Administration
Fibrosis
Therapeutics

Keywords

  • erectile dysfunction
  • intracavernosal injection
  • vasoactive drugs

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Pharmacotherapy in erectile dysfunction agents for self-injection programs and alternative application models. / Hedlund, H.; Hedlund, P.

In: Scandinavian Journal of Urology and Nephrology, Supplement, Vol. 30, No. 179, 1996, p. 129-138.

Research output: Contribution to journalArticle

@article{d5f41796db4c45efb8678b3e4938f8c1,
title = "Pharmacotherapy in erectile dysfunction agents for self-injection programs and alternative application models",
abstract = "Previously, men with erectile dysfuncion (ED) were frequently treated with penile prosthesis implants or considered to have psychogenic impotence. Since the reports by Virag and Brindley in 1982 and 1983, pharmacotherapy, by self-injection programs has become a new therapeutic concept for impotent men. In clinical practice, this application model has been generally accepted as the 'golden standard' in the treatment of ED. Papaverine was first used as monotherapy, but because of side-effects such as prolonged erection, priapism, and fibrosis of the corpus cavernosum, single use of the drug was abandoned. Instead, papaverine was introduced in mixtures, e.g. together with α-adrenoceptor-blockers as phentolamine, and/or prostaglandin E1 (PGE 1). In these 'cocktails', the dose of papaverine is reduced to 10-15 mg, compared to the high doses (80-120 mg) that were used initially. By having two or more drugs in the mixture, a facilitating cascade effect is probably obtained. PGE 1 is the only drug that has been approved by the FDA and is today registered in more than 50 countries. Other combination therapies such as vasoactive intestinal polypeptide + phentolamine, or calcitonin gene-related peptide + PGE 1, have been suggested as suitable alternatives for intracavernosal injection. Transdermal and intraurethral application models may be considered in selected patients. Recently, oral administration of a phosphodiesterase inhibitor (UK-92.480) was reported to improve penile erection in patients with psychogenic impotence. Further clinical results from controlled trials will probably explain if this new oral drug will compete with PGE 1 or other agents in self-injection programs.",
keywords = "erectile dysfunction, intracavernosal injection, vasoactive drugs",
author = "H. Hedlund and P. Hedlund",
year = "1996",
language = "English",
volume = "30",
pages = "129--138",
journal = "Scandinavian Journal of Urology and Nephrology, Supplement",
issn = "0300-8886",
publisher = "Taylor and Francis Ltd.",
number = "179",

}

TY - JOUR

T1 - Pharmacotherapy in erectile dysfunction agents for self-injection programs and alternative application models

AU - Hedlund, H.

AU - Hedlund, P.

PY - 1996

Y1 - 1996

N2 - Previously, men with erectile dysfuncion (ED) were frequently treated with penile prosthesis implants or considered to have psychogenic impotence. Since the reports by Virag and Brindley in 1982 and 1983, pharmacotherapy, by self-injection programs has become a new therapeutic concept for impotent men. In clinical practice, this application model has been generally accepted as the 'golden standard' in the treatment of ED. Papaverine was first used as monotherapy, but because of side-effects such as prolonged erection, priapism, and fibrosis of the corpus cavernosum, single use of the drug was abandoned. Instead, papaverine was introduced in mixtures, e.g. together with α-adrenoceptor-blockers as phentolamine, and/or prostaglandin E1 (PGE 1). In these 'cocktails', the dose of papaverine is reduced to 10-15 mg, compared to the high doses (80-120 mg) that were used initially. By having two or more drugs in the mixture, a facilitating cascade effect is probably obtained. PGE 1 is the only drug that has been approved by the FDA and is today registered in more than 50 countries. Other combination therapies such as vasoactive intestinal polypeptide + phentolamine, or calcitonin gene-related peptide + PGE 1, have been suggested as suitable alternatives for intracavernosal injection. Transdermal and intraurethral application models may be considered in selected patients. Recently, oral administration of a phosphodiesterase inhibitor (UK-92.480) was reported to improve penile erection in patients with psychogenic impotence. Further clinical results from controlled trials will probably explain if this new oral drug will compete with PGE 1 or other agents in self-injection programs.

AB - Previously, men with erectile dysfuncion (ED) were frequently treated with penile prosthesis implants or considered to have psychogenic impotence. Since the reports by Virag and Brindley in 1982 and 1983, pharmacotherapy, by self-injection programs has become a new therapeutic concept for impotent men. In clinical practice, this application model has been generally accepted as the 'golden standard' in the treatment of ED. Papaverine was first used as monotherapy, but because of side-effects such as prolonged erection, priapism, and fibrosis of the corpus cavernosum, single use of the drug was abandoned. Instead, papaverine was introduced in mixtures, e.g. together with α-adrenoceptor-blockers as phentolamine, and/or prostaglandin E1 (PGE 1). In these 'cocktails', the dose of papaverine is reduced to 10-15 mg, compared to the high doses (80-120 mg) that were used initially. By having two or more drugs in the mixture, a facilitating cascade effect is probably obtained. PGE 1 is the only drug that has been approved by the FDA and is today registered in more than 50 countries. Other combination therapies such as vasoactive intestinal polypeptide + phentolamine, or calcitonin gene-related peptide + PGE 1, have been suggested as suitable alternatives for intracavernosal injection. Transdermal and intraurethral application models may be considered in selected patients. Recently, oral administration of a phosphodiesterase inhibitor (UK-92.480) was reported to improve penile erection in patients with psychogenic impotence. Further clinical results from controlled trials will probably explain if this new oral drug will compete with PGE 1 or other agents in self-injection programs.

KW - erectile dysfunction

KW - intracavernosal injection

KW - vasoactive drugs

UR - http://www.scopus.com/inward/record.url?scp=0030333369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030333369&partnerID=8YFLogxK

M3 - Article

C2 - 8908679

AN - SCOPUS:0030333369

VL - 30

SP - 129

EP - 138

JO - Scandinavian Journal of Urology and Nephrology, Supplement

JF - Scandinavian Journal of Urology and Nephrology, Supplement

SN - 0300-8886

IS - 179

ER -